Whales with a lot of money to spend have taken a noticeably bearish stance on Johnson & Johnson.
Looking at options history for Johnson & Johnson JNJ we detected 11 trades.
If we consider the specifics of each trade, it is accurate to state that 18% of the investors opened trades with bullish expectations and 81% with bearish.
From the overall spotted trades, 2 are puts, for a total amount of $101,915 and 9, calls, for a total amount of $1,285,858.
Expected Price Movements
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $130.0 to $180.0 for Johnson & Johnson over the recent three months.
Insights into Volume & Open Interest
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Johnson & Johnson's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Johnson & Johnson's substantial trades, within a strike price spectrum from $130.0 to $180.0 over the preceding 30 days.
Johnson & Johnson Option Activity Analysis: Last 30 Days
Largest Options Trades Observed:
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|
| JNJ | CALL | TRADE | BEARISH | 04/19/24 | $155.00 | $820.0K | 794 | 808 |
| JNJ | CALL | SWEEP | NEUTRAL | 06/20/25 | $160.00 | $145.3K | 730 | 90 |
| JNJ | CALL | SWEEP | BEARISH | 03/15/24 | $165.00 | $77.7K | 5.2K | 422 |
| JNJ | CALL | SWEEP | NEUTRAL | 04/19/24 | $130.00 | $60.0K | 31 | 19 |
| JNJ | CALL | SWEEP | BULLISH | 01/19/24 | $160.00 | $58.6K | 18.2K | 621 |
About Johnson & Johnson
Johnson & Johnson is the world's largest and most diverse healthcare firm. Three divisions make up the firm: pharmaceutical, medical devices and diagnostics, and consumer. The drug and device groups represent close to 80% of sales and drive the majority of cash flows for the firm. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. The device segment focuses on orthopedics, surgery tools, vision care, and a few smaller areas. The last segment of consumer focuses on baby care, beauty, oral care, over-the-counter drugs, and women's health. The consumer group is being divested in 2023 under the new name Kenvue. Geographically, just over half of total revenue is generated in the United States.
Where Is Johnson & Johnson Standing Right Now?
- Trading volume stands at 2,899,126, with JNJ's price down by -0.67%, positioned at $161.3.
- RSI indicators show the stock to be may be approaching overbought.
- Earnings announcement expected in 7 days.
Professional Analyst Ratings for Johnson & Johnson
Over the past month, 2 industry analysts have shared their insights on this stock, proposing an average target price of $195.0.
- In a cautious move, an analyst from Cantor Fitzgerald downgraded its rating to Overweight, setting a price target of $215.
- Maintaining their stance, an analyst from Raymond James continues to hold a Outperform rating for Johnson & Johnson, targeting a price of $175.
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Johnson & Johnson, Benzinga Pro gives you real-time options trades alerts.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
